Receipt of notification pursuant to Article 69 of the Public Offering Act

The Management Board of Ryvu Therapeutics S.A., with its registeredoffice in Kraków (the "Company"), announces that on June 18, 2025, itreceived a notification from the Company's shareholder, Mr. TadeuszWesołowski, submitted pursuant to Article 69(1)(1) and Article 69a(1)(3)of the Act of July 29, 2005 on Public Offering, Conditions Governing theIntroduction of Financial Instruments to Organized Trading, and PublicCompanies.

According to the content of the notification, as a result of theindirect acquisition of the Company's shares by Mr. Tadeusz Wesołowskiin the transactions disclosed by the Company in current reports No.16/2025 of June 9, 2025, No. 18/2025 of June 12, 2025, and No. 19/2025of June 18, 2025, the total share of Mr. Tadeusz Wesołowski andaffiliated entities in the overall number of votes at the Company'sGeneral Meeting amounts to 5.05% and has not changed.

The full content of the notification is attached to this report.

Disclaimer: This English language translation has been prepared solelyfor the convenience of English-speaking readers. Despite all the effortsdevoted to this translation, certain discrepancies, omissions orapproximations may exist. In case of any differences between the Polishand the English versions, the Polish version shall prevail. RyvuTherapeutics S.A., its representatives and employees decline allresponsibility in this regard.